"We're Positive Into Ph3 Ensifentrine Data In August" - Truist Securities Bullish on Verona Pharma (VRNA) Ahead of Key Readout
Tweet Send to a Friend
Truist Securities analyst Joon Lee reiterated a Buy rating and $18.00 price target on Verona Pharma (NASDAQ: VRNA), following the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
